Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70403 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 28.10.2026. Verfasst von Jiaqi Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, PR China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit nennt 108 Literaturangaben. Gefördert von: Shandong Provincial Graduate Student Excellence and Quality Course Project, Clinical Research Special Project of Shandong University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains one of the leading causes of cancer‐related incidence and mortality worldwide, with accumulating evidence indicating that its tumorigenesis and progression are tightly linked to epigenetic dysregulation. Histone deacetylases (HDACs) are key epigenetic regulators involved in gene transcription, cell‐cycle regulation, and cancer progression, whereas the therapeutic benefits of conventional HDAC inhibitors are frequently compromised by limited selectivity and resistance development. Recently, dual‐target HDAC inhibitors (HDACis) have attracted considerable attention as an emerging paradigm in anticancer drug development. These multitarget strategies can simultaneously enhance synergistic antitumor efficacy and alleviate the compensatory resistance commonly associated with single‐target therapies via multi‐mechanistic interventions. Accordingly, the concurrent modulation of HDACs and additional therapeutic targets represents a viable therapeutic strategy for CRC. In this review, we systematically summarize the recent progress of dual‐target HDAC is in CRC treatment, with particular emphasis on their therapeutic potential and implications for future translational research and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, PR China.
ORCID-Profile: Jiaqi Yang, Honglei Zhou
Förderung
- Shandong Provincial Graduate Student Excellence and Quality Course Project
- Clinical Research Special Project of Shandong University of Traditional Chinese Medicine
Zitieren
APA
Yang, J., Shi, X., Xu, Y., Kong, Q., Kong, D., Feng, Y., & Zhou, H. (2026). Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70403
Vancouver
Yang J, Shi X, Xu Y, Kong Q, Kong D, Feng Y, et al. Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70403
BibTeX
@article{Yang2026,
author = {Yang, Jiaqi and Shi, Xinyu and Xu, Yang and Kong, Qinghe and Kong, Degang and Feng, Yun and Zhou, Honglei},
title = {Recent Progress in HDAC‐Based Dual‐Target Inhibitors for Colorectal Cancer},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70403}
}
EUVIMED